STAT+: Marea drug cuts type of blood fat in half in study

Marea Therapeutics said Wednesday that an experimental drug reduced by half a type of blood fat called remnant cholesterol — a mid-stage study result that paves the way for further trials and could lead to a new way of treating cardiovascular disease. 

Remnant cholesterol is distinct from LDL (bad) or HDL (good) cholesterol, and elevated levels are associated with a higher risk of serious cardiovascular events even in patients prescribed standard cholesterol-lowering medicines, said Ethan Weiss, Marea’s co-founder and chief scientific officer. 

No drugs currently approved lower remnant cholesterol. 

Continue to STAT+ to read the full story…